Biopharmaceutical company Radius Health filed for an initial public offering on Tuesday that could raise up to $86.25m, less than two months after closing a $91m series D round.

The major institutional shareholders in Radius are private equity firm MPM Capital (which holds 39.2% of Radius’ shares), medical foundation the Wellcome Trust (13.4%), venture capital firms Healthcare Ventures (10.7%), Saints Capital (8.7%), Oxford Bioscience Partners (6.4%), investment firm BB Biotech (8.9%), Biotech Growth (5.7%) and Brookside Capital Partners…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?